Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) saw an uptick in trading volume on Monday . 17,020 shares traded hands during trading, an increase of 347% from the previous session’s volume of 3,810 shares.The stock last traded at $11.30 and had previously closed at $11.1920.
Oxford BioMedica Stock Performance
The business has a fifty day moving average of $10.00 and a 200 day moving average of $8.48. The company has a quick ratio of 1.67, a current ratio of 1.89 and a debt-to-equity ratio of 3.08.
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Further Reading
- Five stocks we like better than Oxford BioMedica
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
